by Clinical Neuropsychologist Online | Saturday, August 31, 2024 | Dementia
Abstract INTRODUCTION Anti-amyloid antibody therapies such as lecanemab are increasingly being used to treat Alzheimer’s disease (AD). These therapies are associated with a high rate of amyloid-related imaging abnormalities (ARIA). METHODS We review the case...
by Clinical Neuropsychologist Online | Friday, August 30, 2024 | Dementia
Abstract INTRODUCTION Cellular prion protein (PrPC) was implicated in amyloid beta (Aβ)-induced toxicity in Alzheimer’s disease (AD), but the precise molecular mechanisms involved in this process are unclear. METHODS Double transgenic mice were generated by...
by Clinical Neuropsychologist Online | Friday, August 30, 2024 | Dementia
Dementia, Volume 24, Issue 2, Page 235-248, February 2025. Dementia is a leading cause of disability, and as the population ages, there will be a greater need for friends and family to care for people with Dementia. Unfortunately, informal care for a person with...
by Clinical Neuropsychologist Online | Friday, August 30, 2024 | Dementia
Dementia, Volume 24, Issue 3, Page 353-367, April 2025. Primary progressive aphasia (PPA) is a neurodegenerative brain disorder characterized by declining language ability. It is a rare, often young-onset dementia with a devastating impact on the work and personal...
by Clinical Neuropsychologist Online | Friday, August 30, 2024 | Dementia
Abstract INTRODUCTION Blood-derived microRNAs (miRNAs) are potential candidates for detecting and preventing subclinical cognitive dysfunction. However, replication of previous findings and identification of novel miRNAs associated with cognitive domains, including...
